| Literature DB >> 35089122 |
Sambit Sundaray1, Siddhartha Mishra2, Subhash Chandra Dash3, Naba Kishore Sundaray3.
Abstract
INTRODUCTION: Microvasculopathy is characterized by progressive structural and functional damage to the microvessels and plays a key role in the pathogenesis of various connective tissue diseases (CTD). Nailfold videocapillaroscopy is an optimal and validated method for analysis of microvascular abnormalities and is able to differentiate secondary Raynaud's phenomenon (RP) of CTD from primary RP and healthy subjects. AIM: To assess and analyze nailfold capillaroscopic findings in Indian subjects with secondary Raynaud and to compare with findings in healthy subjects.Entities:
Year: 2022 PMID: 35089122 PMCID: PMC8798589 DOI: 10.5041/RMMJ.10460
Source DB: PubMed Journal: Rambam Maimonides Med J ISSN: 2076-9172
Figure 1Nailfold Videocapillaroscopy.
Demographic Characteristics of the Study Participants (n=62).
| Characteristics | Cases ( | Controls ( | |
|---|---|---|---|
| Age (years), mean±SD | 41.48±15.88 | 41.81±12.94 | 0.930 |
| Female Sex % ( | 71% (22) | 77% (24) | 0.562 |
| Disease duration (years) | 5.77±4.84 | ||
| DcSSc % ( | 19.4% (6) | ||
| LcSSc % ( | 32.3% (10) | ||
| SLE% ( | 16.1% (5) | ||
| MCTD % ( | 16.1% (5) | ||
| DM % ( | 12.9% (4) | ||
| UCTD % ( | 3.2% (1) |
Independent t test.
Chi-square test.
DcSSc, diffuse cutaneous systemic sclerosis; DM, dermatomyositis; LcSSc, limited cutaneous systemic sclerosis; MCTD, mixed connective tissue diseases; SD, standard deviation; UCTD, undifferentiated connective tissue diseases.
Nailfold Capillaroscopic Changes Among Cases and Controls.
| Parameters | Controls ( | DcSSc ( | LcSSc ( | SLE ( | MCTD ( | DM ( | UCTD ( | Cases ( | |
|---|---|---|---|---|---|---|---|---|---|
| Mean loop length (μm) | 282.97± 28.94 | 248.17±77.57 | 216.50±80.25 | 228.60±35.47 | 217.60±45.86 | 235±25.83 | 173 | 225.74±60.79 | 0.002 |
| Mean loop width (μm) | 13.13±3.44 | 25±19.92 | 40.50±21.79 | 34.20±16.63 | 19.20±7.53 | 19.50±12.12 | 12.0 | 29.42±18.90 | 0.0001 |
| Mean capillary density (/mm) | 7.39±1.3 | 3.0±1.55 | 4.7±2.06 | 6.6±2.88 | 3.2±2.28 | 5.0±2.16 | 9.0 | 4.61±2.47 | 0.0001 |
| Tortuosity % ( | 10% (3) | 100% (6) | 80% (8) | 80% (4) | 60% (3) | 50% (2) | 100% (1) | 77% (24) | 0.0001 |
| Giant capillary % ( | 0% (0) | 16.6% (1) | 40% (4) | 40% (2) | 0% (0) | 0% (0) | 0% (0) | 22.6% (7) | 0.004 |
| Dilated capillary % ( | 0% (0) | 33.3% (2) | 40% (4) | 40% (2) | 60% (3) | 25% (1) | 0% (0) | 38.7% (12) | 0.0001 |
| Microhemorrhage % ( | 0% (0) | 0% (0) | 20% (2) | 40% (2) | 0% (0) | 25% (1) | 0% (0) | 16% (5) | 0.005 |
| Neoangiogenesis % ( | 0% (0) | 66.6% (4) | 50% (5) | 40% (2) | 40% (2) | 50% (2) | 0% (0) | 48% (15) | 0.0001 |
| Avascular area % ( | 0% (0) | 83.3% (5) | 50% (5) | 20% (1) | 100% (5) | 50% (2) | 0% (0) | 58.0% (18) | 0.0001 |
| Scleroderma pattern % ( | 0% (0) | 66.6% (4) | 60% (6) | 0% (0) | 60% (3) | 25% (1) | 0% (0) | 45.1% (14) | 0.0001 |
| Non-specific pattern % ( | 0% (0) | 33.3% (2) | 30% (3) | 80% (4) | 40% (2) | 50% (2) | 100% (1) | 45.1% (14) | 0.0001 |
ANOVA test.
Fisher’s exact test.
DcSSc, diffuse cutaneous systemic sclerosis; DM, diabetes mellitus; LcSSc, limited cutaneous systemic sclerosis; MCTD, mixed connective tissue disease; SLE, systemic lupus erythematosus; UCTD, undifferentiated connective tissue disease.
Figure 2Capillaroscopic Findings of Morphologic Aberrations.
A: Avascular areas; B: Neoangiogenesis; C: Dilated capillary; D: Ramified capillaries; E: Giant capillary; F: Tortuosity.
Scleroderma Patterns in Connective Tissue Diseases.
| Scleroderma Patterns | Total ( | DcSSc ( | LcSSc ( | SLE ( | MCTD ( | DM ( | UCTD ( |
|---|---|---|---|---|---|---|---|
| Early Pattern | 50% (7) | 33.3% (2) | 30% (3) | 0 | 20% (1) | 25% (1) | 0 |
| Active Pattern | 21.4% (3) | 16.6% (1) | 10% (1) | 0 | 20% (1) | 0 | 0 |
| Late Pattern | 28.6% (4) | 33.3% (2) | 10% (1) | 0 | 20% (1) | 0 | 0 |
DcSSc, diffuse cutaneous systemic sclerosis; DM, dermatomyositis; LcSSc, limited cutaneous systemic sclerosis; MCTD, mixed connective tissue diseases; SLE, systemic lupus erythematosus; UCTD, undifferentiated connective tissue diseases.